Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + Trastuzumab + Pembrolizumab + mFOLFOX in HER2+ Gastroesophageal Cancers
NCT06109467Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2024
- Primary completion
- Mar 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of neratinib in gastroesophageal junction cancer, gastric cancer (GC), sponsored by Moffitt Cancer Center. Started Jan 2024; status: active, not recruiting.
02
Drugs
neratinib
03
Conditions
gastroesophageal junction cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT06109467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109467.